All In Biotech

Drug Trial Radar · NCT03418480

HARE-40: HPV Anti-CD40 RNA vaccinE

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Apr 11, 2017

Primary completion

Nov 1, 2023

Study completion Jan 24, 2024

Sponsor

Lead sponsor
University of SouthamptonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioNTech SE
First posted
Feb 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will perform intrapatient dose escalation in patients with previously treated HPV16+ Head \& Neck Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV vaccine. Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer (head and neck, anogenital, penile, cervical and other) using a single cohort to establish a safe, tolerable and recommended dose of HPV vaccine.

Conditions

  • Human Papilloma Virus Related Carcinoma
  • Head and Neck Neoplasm
  • Cervical Neoplasm
  • Penile Neoplasms Malignant
  • Unknown Primary Tumors

Interventions

  • BNT113Drug

    Intravenous vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT) according to CTCAE version 4.03 (Arm 1A and Arm 1B)Time frame: Adverse Events reported from the time of first vaccine administration up to 28 days after the last administration. Serious Adverse Events suspected to be related to study drug to be reported until the end of follow up.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Univeristy Hospitals Southampton NHS Foundation Trust

    Southampton, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.